| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Over the last 12 months, insiders at Gain Therapeutics, Inc. have bought $0 and sold $0 worth of Gain Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Gain Therapeutics, Inc. have bought $120,811 and sold $5,057 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $49,940 was made by Islam Khalid (Executive Chairman) on 2024‑08‑09.
| 2024-08-09 | Islam Khalid | Executive Chairman | 50,000 0.2022% | $1.00 | $49,940 | +88.51% | ||
| 2024-08-09 | Mack Gene | CFO and Interim CEO | 14,400 0.0589% | $1.01 | $14,544 | +88.51% | ||
| 2024-07-01 | RICHMAN ERIC I | director | 17,000 0.0902% | $1.22 | $20,670 | +64.73% | ||
| 2024-03-28 | Riley Jeffrey Scott | director | 30,000 0.1501% | $3.86 | $115,770 | -45.09% | ||
| 2023-12-21 | Sale | Alder Matthias | Chief Executive Officer | 206 0.0014% | $2.46 | $507 | -6.00% | |
| 2023-12-07 | Sale | Alder Matthias | Chief Executive Officer | 1,820 0.0122% | $2.50 | $4,550 | -2.78% | |
| 2022-05-25 | RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 2,482 0.0203% | $2.58 | $6,404 | +43.21% | ||
| 2022-05-19 | RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 9,256 0.0816% | $2.83 | $26,194 | +39.63% | ||
| 2022-05-19 | Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 3,000 0.0252% | $2.70 | $8,100 | +39.63% | ||
| 2021-08-16 | RICHMAN ERIC I | Chief Executive Officer | 4,922 0.042% | $7.87 | $38,716 | -45.68% |
| RICHMAN ERIC I | director | 289629 0.679% | $521,332.20 | 4 | 0 | +25.47% |
| Islam Khalid | Executive Chairman | 50000 0.1172% | $90,000.00 | 1 | 0 | +88.51% |
| Riley Jeffrey Scott | director | 30000 0.0703% | $54,000.00 | 1 | 0 | <0.0001% |
| Mack Gene | CFO and Interim CEO | 14400 0.0338% | $25,920.00 | 1 | 0 | +88.51% |
| Alder Matthias | Chief Executive Officer | 5286 0.0124% | $9,514.80 | 0 | 2 | |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 3000 0.007% | $5,400.00 | 1 | 0 | +39.63% |
$5,806,764 | 117 | -33.92% | $80.26M | |
$84,911,583 | 59 | 17.82% | $89.28M | |
$1,701,941 | 56 | 17.58% | $89.56M | |
$19,705,388 | 47 | 86.26% | $84.01M | |
$77,146,704 | 43 | 13.28% | $87.28M | |
$909,129 | 37 | 42.19% | $72.52M | |
$6,818,859 | 36 | 47.81% | $72.11M | |
$115,646,156 | 35 | 16.45% | $65.09M | |
$2,783,837 | 22 | -18.19% | $64.87M | |
$1,602,584 | 20 | 15.26% | $80.23M | |
$3,606,967 | 19 | 9.60% | $85.69M | |
$8,403,939 | 18 | 68.26% | $87.94M | |
Gain Therapeutics, Inc. (GANX) | $280,338 | 8 | 34.18% | $76.78M |
$32,684,649 | 8 | -15.84% | $89.65M | |
$22,090,972 | 7 | -3.49% | $70.06M | |
$106,599,960 | 6 | -7.63% | $68.8M | |
$401,951 | 4 | 57.41% | $67.07M | |
$10,629 | 1 | -0.59% | $63.58M | |
$4,030 | 1 | 9.14% | $72.57M |
| Increased Positions | 36 | +102.86% | 5M | +104.67% |
| Decreased Positions | 12 | -34.29% | 812,650 | -18.72% |
| New Positions | 21 | New | 2M | New |
| Sold Out Positions | 9 | Sold Out | 636,310 | Sold Out |
| Total Postitions | 59 | +68.57% | 8M | +85.95% |
| Jones Financial Companies Lllp | $2,152.00 | 1.78% | 676,822 | -66 | <0.01% | 2025-09-30 |
| Dme Capital Management, Lp | $1,800.00 | 1.49% | 566,130 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $1,699.00 | 1.41% | 534,352 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $1,188.00 | 0.98% | 373,558 | +211,742 | +130.85% | 2025-09-30 |
| Geode Capital Management, Llc | $1,094.00 | 0.91% | 344,146 | +53,684 | +18.48% | 2025-09-30 |
| Cambridge Investment Research Advisors, Inc. | $1,013.00 | 0.84% | 318,645 | +139,145 | +77.52% | 2025-09-30 |
| Marshall Wace, Llp | $557.00 | 0.46% | 175,107 | -101,326 | -36.66% | 2025-09-30 |
| Morgan Stanley | $495.00 | 0.41% | 155,675 | +79,163 | +103.47% | 2025-09-30 |
| Ubs Group Ag | $447.00 | 0.37% | 140,677 | +108,042 | +331.06% | 2025-09-30 |
| Renaissance Technologies Llc | $401.00 | 0.33% | 126,100 | +32,100 | +34.15% | 2025-09-30 |